Literature DB >> 18209989

[Progress in immunosuppression].

C P Strassburg1, M J Bahr, T Becker, J Klempnauer, M P Manns.   

Abstract

The success of transplantation with good long-term outcome is closely related to the possibilities of iatrogenic immunosuppression. Progress in immunosuppression combines basic scientific research of alloimmunity with practical clinical management of transplanted patients, their underlying diseases, and management of immunosuppressant side effects. Calcineurin inhibitors and steroids form the basis of immunosuppression in liver transplantation. To prevent steroid side effects and most importantly nephrotoxicity, the roles of antimetabolites such as mycophenolate and calcineurin inhibitor reduction have become more important. Developments in the 1990s provided specific antibodies and induction protocols renabling the delayed application of calcineurin inhibitors and a reduction in side effects. Against the background of a range of indications reaching from chronic viral infection to tumors, the progress of immunosuppression is characterized by the calculated combination of synergistic individual immunosuppressants. Novel drugs and strategies for the induction of tolerance are under development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18209989     DOI: 10.1007/s00104-007-1456-8

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  48 in total

Review 1.  Incidence, timing, and risk factors for acute and chronic rejection.

Authors:  J Neuberger
Journal:  Liver Transpl Surg       Date:  1999-07

Review 2.  Immunosuppression: today, tomorrow, and withdrawal.

Authors:  Ryutaro Hirose; Flavio Vincenti
Journal:  Semin Liver Dis       Date:  2006-08       Impact factor: 6.115

3.  Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients.

Authors:  Thomas Decaens; Françoise Roudot-Thoraval; Solange Bresson-Hadni; Carole Meyer; Jean Gugenheim; Francois Durand; Pierre-Henri Bernard; Olivier Boillot; Philippe Compagnon; Yvon Calmus; Jean Hardwigsen; Christian Ducerf; Georges-Philippe Pageaux; Sébastien Dharancy; Olivier Chazouillères; Daniel Cherqui; Christophe Duvoux
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

4.  Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy.

Authors:  James D Eason; Satheesh Nair; Ari J Cohen; Jamie L Blazek; George E Loss
Journal:  Transplantation       Date:  2003-04-27       Impact factor: 4.939

5.  Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction.

Authors:  Matthew Kh Hong; Peter W Angus; Robert M Jones; Rhys B Vaughan; Paul J Gow
Journal:  Clin Transplant       Date:  2005-04       Impact factor: 2.863

6.  Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial.

Authors:  Kazuaki Inoue; Kazuhiko Sekiyama; Masaya Yamada; Tsunamasa Watanabe; Hiroshi Yasuda; Makoto Yoshiba
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

7.  A model to predict severe HCV-related disease following liver transplantation.

Authors:  Marina Berenguer; Jeffrey Crippin; Robert Gish; Nathan Bass; Alan Bostrom; George Netto; Judy Alonzo; Richard Garcia-Kennedy; Jose-Miguel Rayón; Teresa L Wright
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

8.  A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.

Authors:  Christopher J E Watson; Alexander E S Gimson; Graeme J Alexander; Michael E D Allison; Paul Gibbs; Jane C Smith; Christopher R Palmer; J Andrew Bradley
Journal:  Liver Transpl       Date:  2007-12       Impact factor: 5.799

9.  Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice.

Authors:  Gudrun E Koehl; Joachim Andrassy; Markus Guba; Sebastian Richter; Alexander Kroemer; Marcus N Scherer; Markus Steinbauer; Christian Graeb; Hans J Schlitt; Karl-Walter Jauch; Edward K Geissler
Journal:  Transplantation       Date:  2004-05-15       Impact factor: 4.939

10.  Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer.

Authors:  Jonathan D Mosley; John T Poirier; Darcie D Seachrist; Melissa D Landis; Ruth A Keri
Journal:  Mol Cancer Ther       Date:  2007-08       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.